Dr. Agarwal’s Health Care Limited announced its unaudited consolidated financial results for the half year ended September 30, 2026. The company reported a substantial 28.7% year-on-year growth in revenue from operations, reaching INR 1,269 Crores. EBITDA saw a 27.0% increase to INR 362 Crores, while Profit After Tax grew by an impressive 50.1% to INR 112 Crores.
Strong Financial Performance for H1 FY27
Dr. Agarwal’s Health Care Limited has announced robust financial results for the half year ended September 30, 2026 (H1’FY27). The company’s Revenue from Operations witnessed a significant year-on-year increase of 28.7%, amounting to INR 1,269 Crores. This growth trajectory was also reflected in the company’s EBITDA, which rose by 27.0% to INR 362 Crores, with EBITDA margins holding steady at 28.2%.
Profitability Surges
The company’s Profit After Tax (PAT) demonstrated exceptional growth, surging by 50.1% to INR 112 Crores for the half year. PAT margins improved to 8.7% from 7.4% in the previous year. In the second quarter (Q2’FY27) specifically, revenue from operations grew by 31.4% YoY to INR 655 Crores, and Profit After Tax saw a substantial increase of 55.8% to INR 57 Crores.
Operational Highlights and Expansion
As of September 30, 2026, the company’s network expanded to 324 facilities, with 39 new centers added during the half year. A total of 186,923 surgeries were performed in H1’FY27, marking an 18.8% YoY growth. The company also highlighted the opening of the world’s first dedicated Pinhole Pupilloplasty (PPP) center at its Chennai flagship facility, underscoring its commitment to clinical innovation.
Leadership Appointment
In a significant corporate development, Dr. Amar Agarwal has been appointed and re-designated as the Executive Chairman (Whole-Time Director) of the Company. This appointment is effective from November 01, 2026, for a period of three years. This change follows the effectiveness of the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. The terms and remuneration for Dr. Amar Agarwal will remain identical to those he previously drew at Dr. Agarwal’s Eye Hospital Limited, subject to member approval.
Postal Ballot for Governance Change
The appointment and re-designation of Dr. Amar Agarwal will be subject to the consent of the company’s members through a Postal Ballot process, in accordance with the Companies Act, 2013.
Auditor’s Review
Independent auditors S.R. Batliboi & Associates LLP have reviewed the accompanying unaudited consolidated financial results. They have expressed an unmodified conclusion, stating that nothing has come to their attention that causes them to believe the statement contains any material misstatement.
Source: BSE
